- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.07. | RACURA ONCOLOGY LTD: Racure Oncology Techknow Invest Presentation | 1 | ASX | ||
| 29.07. | RACURA ONCOLOGY LTD: First HARNESS-1 Patient Safely Treated with RC220 | 2 | ASX | ||
| 28.07. | RACURA ONCOLOGY LTD: June 2026 Quarterly Activities Report and Appendix 4C | 1 | ASX | ||
| RACURA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 24.07. | HotCopper Highlights, Week 30: American T&A acquisition, PolyNovo pressure, & Racura trials | 2 | The Market Online Australia | ||
| 13.07. | RACURA ONCOLOGY LTD: Notification of cessation of securities - RAC | - | ASX | ||
| 09.07. | RACURA ONCOLOGY LTD: Racura to Present CPACS Data at GCOS 2026 | - | ASX | ||
| 06.07. | RACURA ONCOLOGY LTD: Racura Oncology New Zealand Investor Events | - | ASX | ||
| 03.07. | Racura Oncology (ASX:RAC) unlocks two top-tier cancer centres for HARNESS-1 enrolment push | 1 | Stocks Down Under | ||
| 03.07. | RACURA ONCOLOGY LTD: Bellberry Ethics Approval Activates New HARNESS Trial Sites | - | ASX | ||
| 02.07. | RACURA ONCOLOGY LTD: Notification of cessation of securities - RAC | - | ASX | ||
| 25.06. | Racura doses first patient in lung cancer combination trial | 1 | Investing.com | ||
| 25.06. | Racura Oncology Treats First Patient in Harness-1 EGFRm Lung Cancer Trial | 1 | smallcaps.com.au | ||
| 25.06. | RACURA ONCOLOGY LTD: Racura Treats First Patient in HARNESS-1 Lung Cancer Trial | - | ASX | ||
| 16.06. | Racura Oncology Secures A$34.3 Million to Propel Clinical Trials | 1 | Finance News Network | ||
| 16.06. | RACURA ONCOLOGY LTD: Racura Oncology Investor Briefings Perth & Auckland | - | ASX | ||
| 16.06. | RACURA ONCOLOGY LTD: Racura raised $34.3m to Advance Three Oncology Trials | - | ASX | ||
| 16.06. | RACURA ONCOLOGY LTD: Cleansing Notice | - | ASX | ||
| 16.06. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 11.06. | RACURA ONCOLOGY LTD: Cleansing Notice | - | ASX | ||
| 11.06. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX |
1 2 3 4 5 Weiter >>
85 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERA THERAPEUTICS | 31,630 | 0,00 % | Goldman Sachs lowers Vera Therapeutics stock price target to $80 | ||
| SUMMIT THERAPEUTICS | 13,350 | 0,00 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| QIAGEN | 37,290 | -0,98 % | Qiagen-Aktie: Jetzt auf Fünfmonatshoch - lohnt sich der Einstieg? | Qiagen-Aktien legen heute kräftig zu. An der Frankfurter Börse kletterten die Papiere des Diagnostikspezialisten um 4 Prozent nach oben und markierten damit den höchsten Stand seit fünf Monaten. Der... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,56 | +0,01 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| ERASCA | 18,390 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 367,40 | +0,16 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 21,625 | -0,02 % | Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX, | LONDON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 27, 2026, driven by key catalysts including prospective clinical trial results, and the launch of new services.Dyne... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,610 | +0,04 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,950 | +0,05 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
| KYMERA THERAPEUTICS | 117,37 | 0,00 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| CLIMB BIO | 16,340 | +0,06 % | Climb Bio, Inc. - 8-K, Current Report | ||
| CG ONCOLOGY | 75,10 | +0,09 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,690 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,195 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 76,69 | -0,08 % | Kiniksa auf Wachstumskurs: ARCALYST-Umsatz steigt, Pipeline wird ausgebaut |
Das Unternehmen RACURA ONCOLOGY LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,170 Euro und damit -0,85 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RACURA ONCOLOGY LTD finden Sie auf Wallstreet Online.